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mThe ISPOR-SMDM Modeling Good Research Practices Task Force
Report in this issue is a welcome update to the previous ISPOR
guidance published in 2003 [1]. In the past decade, cost-effective-
ness analysis has proliferated and its use in coverage and pricing
decisions by governmental authorities has spread across much of
Europe and elsewhere [2]. Modeling methodology has evolved in
ays that should improve its usefulness, but despite these en-
ancements, significant challenges to adoption by US payers re-
ain. The Task Force members have identified several challenges
nd suggested ways to address barriers to the acceptance of eco-
omic models as decision support tools. To do this, it will be nec-
ssary to gain a better understanding of the decision support
eeds of payers.
Caro and colleagues [3] observed that models reduce complex
ealities to a set of essential elements. Given the complexity of
isease, the interpatient variability, and the diversity of health
are systems and processes, reducing medical reality and identi-
ying the elements that are essential to a particular health care
ecision is a daunting task. Creating a useful simulation of a med-
cal decision will always require a great deal of simplification. The
ask Force report first addresses identifying the principal deter-
inants of decision outcomes. Decision analysis is most needed
hen we are least certain how to proceed and probably cannot
dentify all the relevant elements or understand all the relation-
hips between them. Selecting the best model structure and lim-
ting the number of inputs to reduce complexity to a manageable
evel may require subjective judgment, upon which stakeholders
ay disagree. To achieve understanding among stakeholders, a
inimum threshold of agreement must be reached.
The first step in the logical process outlined by the Task Force
s conceptualization [3]. It is unlikely that a useful model will
esult without careful thought and planning at its inception.
efore drug manufacturers appreciated this, they often left out-
omes model planning until after the pivotal trials, only to find
hat necessary inputs to the model could not be obtained from
rial results. Consultation with pharmacoeconomists and deci-
ion makers earlier in the product development process can
revent this impasse, but it requires a paradigm shift from trial
esigns driven by regulatory requirements to trials that support
convincing value proposition.
Models must be grounded in clinical reality as experienced by
he decisionmakers whowill use them, andmodel structuremust
eflect that reality. This involves a trade-off between clarity and
omplexity. Themodel should be detailed enough to credibly sim-
late reality but simple enough to be understood by clinicianswith
inimal training in economics or decision analysis. This is best
chieved by working with end users and incorporating their feed-
ack in successive iterations of the model, a process that requiresSource of financial support: No proprietary information is includedommitment by both parties. To be helpful, end users must learn
nough about models to offer valid criticism, but they need not
ecome pharmacoeconomists. Decision analysts must under-
tand key clinical aspects of the decision problem, but nonclini-
ians can do this with the help of clinical experts. Decisionmakers
an identify the perspectives, time horizons, comparators, set-
ings, and target populations that will be most useful to them.
Traditional audiences for decision models have been clini-
ians, payers, and policymakers, but the US government’s new
rogram of Patient-Centered Outcomes Research [4] suggests a
uture role for patient perspective models as well. Patient-Cen-
ered Outcomes Research views the patient as decisionmaker and
rincipal consumer of decision support information. As more pa-
ients accept this role, model builders may be asked to present
heir evidence in ways that facilitate shared decision making. We
hould learn to communicate model results in ways that are cred-
ble, meaningful, and actionable for nonprofessionals.
The last article in this series addresses transparency and vali-
ation [5]. This is the other point where thoughtful dialogue with
ecision makers can be useful. Transparency requires both tech-
ical and nontechnicalmodel documentation. Most end users will
robably want the nontechnical version, but if they have or can
onsult technical expertise, they will need a detailed methodo-
ogic description. The validation process should be transparently
escribed. Clinicians usually focus on reviewing the input data
ources and assumptions, clinical credibility of the decision tree,
nd other aspects about which they are most knowledgeable and
ay engage a pharmacoeconomist for technical validation. If the
ethodology includes specific intellectual property, a nondisclo-
ure agreement is appropriate.
Many of these concerns about economic models apply to ret-
ospective observational studies as well. Payers expect manufac-
urers to design studies with a subtle bias in favor of their product,
nd there is reason for this concern [6]. Because ISPOR is also
articipating in the Comparative Effectiveness Research Collabor-
tive Initiative, the work groups in that project should examine
he modeling task force reports for common ground. Central to
ayer acceptance of both study types is methodologic rigor and
ransparency, along with tools for the evaluation of the studies
hat create a reasonably level playing field on which the evidence
an be presented and assessed.
Since our plenary session panel discussion onways to improve
he value of modeling to payers and providers was held at the
SPOR Annual International Meeting in May 2010, the dialogue be-
ween drug manufacturers’ health outcomes departments and
ayers has improved both qualitatively and quantitatively. We
ope that this trend continues and produces pharmacoeconomic
odels that are more useful to decision makers.. This project was not sponsored.
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